Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim A Papp

Showing results (171-180 of 219) with videos related to

Pageof 22
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|March 6, 2025
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
Journal of Drugs in Dermatology : JDD|May 12, 2016
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 TrialsM Alan Menter, Kim A Papp, Jennifer Cather, et al.
The Journal of Allergy and Clinical Immunology|October 4, 2022
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studiesEmma Guttman-Yassky, Jacob P Thyssen, Jonathan I Silverberg, et al.
Journal of the American Academy of Dermatology|August 8, 2023
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-upKim A Papp, Andrew Blauvelt, Lluís Puig, et al.
Lancet (London, England)|August 12, 2018
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trialsKenneth B Gordon, Bruce Strober, Mark Lebwohl, et al.
Journal of Cutaneous Medicine and Surgery|November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus DocumentMelinda J Gooderham, Chih-Ho Hong, Lorne Albrecht, et al.
Journal of Cutaneous Medicine and Surgery|November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic DermatitisChih-Ho Hong, Melinda J Gooderham, Lorne Albrecht, et al.
The New England Journal of Medicine|April 20, 2017
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque PsoriasisKim A Papp, Andrew Blauvelt, Michael Bukhalo, et al.
The British Journal of Dermatology|July 25, 2023
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)Linda F Stein Gold, Jerry Bagel, Stephen K Tyring, et al.
Dermatology and Therapy|July 6, 2023
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Barbara Melosky, Sandeep Sehdev, et al.
Pageof 22

Showing results (171-180 of 219) with videos related to

Sort By:
Pageof 22
Journal of the European Academy of Dermatology and Venereology : JEADV|March 6, 2025
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
Journal of Drugs in Dermatology : JDD|May 12, 2016
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 TrialsM Alan Menter, Kim A Papp, Jennifer Cather, et al.
The Journal of Allergy and Clinical Immunology|October 4, 2022
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studiesEmma Guttman-Yassky, Jacob P Thyssen, Jonathan I Silverberg, et al.
Journal of the American Academy of Dermatology|August 8, 2023
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-upKim A Papp, Andrew Blauvelt, Lluís Puig, et al.
Lancet (London, England)|August 12, 2018
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trialsKenneth B Gordon, Bruce Strober, Mark Lebwohl, et al.
Journal of Cutaneous Medicine and Surgery|November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus DocumentMelinda J Gooderham, Chih-Ho Hong, Lorne Albrecht, et al.
Journal of Cutaneous Medicine and Surgery|November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic DermatitisChih-Ho Hong, Melinda J Gooderham, Lorne Albrecht, et al.
The New England Journal of Medicine|April 20, 2017
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque PsoriasisKim A Papp, Andrew Blauvelt, Michael Bukhalo, et al.
The British Journal of Dermatology|July 25, 2023
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)Linda F Stein Gold, Jerry Bagel, Stephen K Tyring, et al.
Dermatology and Therapy|July 6, 2023
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Barbara Melosky, Sandeep Sehdev, et al.
Pageof 22